Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc., a prominent player in the ophthalmic pharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has rapidly established itself as a leader in developing innovative therapies for eye diseases, particularly glaucoma and retinal disorders. Aerie's core products, including the unique eye drops Rhopressa® and Rocklatan®, are designed to lower intraocular pressure, setting them apart in a competitive market.
With a strong focus on research and development, Aerie has achieved significant milestones, including successful product launches and expanding its operational footprint across North America and Europe. The company’s commitment to advancing eye care has positioned it favourably within the industry, earning recognition for its contributions to improving patient outcomes and enhancing the quality of life for those affected by vision-related conditions.
-2 vs industry average
Aerie Pharmaceuticals, Inc.’s score of 36 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Aerie Pharmaceuticals, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Aerie Pharmaceuticals, Inc. yet.
Aerie Pharmaceuticals, Inc.'s reported carbon emissions
Aerie Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is part of a merged entity structure, inheriting emissions data from its parent company, Alcon Inc., at a cascade level of 2. However, no specific emissions figures or reduction targets have been disclosed.
Aerie Pharmaceuticals has not publicly committed to any specific climate initiatives or reduction targets, as indicated by the absence of documented reduction initiatives or Science-Based Targets Initiative (SBTi) commitments. The lack of emissions data and climate pledges suggests that Aerie Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy.
As the pharmaceutical industry increasingly focuses on sustainability, Aerie Pharmaceuticals may benefit from aligning its practices with industry standards and setting measurable targets to reduce its carbon footprint in the future.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Aerie Pharmaceuticals, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Aerie Pharmaceuticals, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project